Aspa; aspartoacylase; RP23-213I10.1; Acy-2,; Acy2; nur7; OTTMUSP00000006437; aminoacylase 2; aminoacylase-2; aspartoacylase (aminoacylase) 2; small lethargic; Aspa antibody; aspartoacylase antibody; RP23-213I10.1 antibody; Acy-2; antibody; Acy2 antibody; nur7 antibody; OTTMUSP00000006437 antibody; aminoacylase 2 antibody; aminoacylase-2 antibody; small lethargic antibody; Aspa (mouse)

For Research Use Only. Not for use in diagnostic procedures.

Polyclonal

Goat

Purified from goat serum by ammonium sulphate precipitation followed by antigen affinity chromatography using the immunizing peptide.

Supplied at 0.5 mg/ml in Tris saline, 0. 02% sodium azide, pH7.3 with 0.5% bovine serum albumin.

100ug specific antibody in 200ul (lot specific)

Aliquot and store at -20 degree C. Minimize freezing and thawing.

Manufactured in an ISO 9001:2008 Certified Laboratory.

Small volumes of anti-Aspa antibody vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.

Peptide ELISA (EIA), Western Blot (WB)

Peptide ELISA: Antibody detection limit dilution 1: 8000.
Western Blot: Approx 35kDa band observed in Mouse and Rat Kidney lysates (calculated MW of 35.3kDa according to NP_075602.2). Recommended concentration: 0.01-0.03ug/ml.

(0. 01ug/ml) staining of Mouse Kidney lysate (35ug protein in RIPA buffer). Primary incubation was 1 hour. Detected by chemiluminescence.

35,345 Da

aspartoacylase

aspartoacylase

Aspartoacylase

ACY-2??[Similar Products]

ACY2_MOUSE

This gene encodes an enzyme that deacteylates N-acetyl-L-aspartic acid (NAA) in the brain to yield acetate and L-aspartate. In humans, alterations in neuronal NAA concentration are associated with many neurodegenerative diseases (decrease associated with epilepsy, multiple sclerosis, myotrophic lateral sclerosis, and Alzheimer's disease; increase associated with Canavan disease). In mouse, mutations in this gene, which cause accumulation of NAA, result in demyelination and spongy degeneration in the CNS and serve as a pathophysiological model for Canavan disease. [provided by RefSeq, Dec 2012]

ASPA: Catalyzes the deacetylation of N-acetylaspartic acid (NAA) to produce acetate and L-aspartate. NAA occurs in high concentration in brain and its hydrolysis NAA plays a significant part in the maintenance of intact white matter. In other tissues it act as a scavenger of NAA from body fluids. Defects in ASPA are the cause of Canavan disease (CAND); also known as spongy degeneration of the brain. CAND is a rare neurodegenerative condition of infancy or childhood characterized by white matter vacuolization and demeylination that gives rise to a spongy appearance. The clinical features are onset in early infancy, atonia of neck muscles, hypotonia, hyperextension of legs and flexion of arms, blindness, severe mental defect, megalocephaly, and death by 18 months on the average. Belongs to the AspA/AstE family. Aspartoacylase subfamily.

Protein type: EC 3.5.1.15; Amino Acid Metabolism - histidine; Amino Acid Metabolism - alanine, aspartate and glutamate; Hydrolase

Cellular Component: cytoplasm; cytosol; nucleus

Molecular Function: aminoacylase activity; aspartoacylase activity; hydrolase activity; hydrolase activity, acting on carbon-nitrogen (but not peptide) bonds, in linear amides; hydrolase activity, acting on ester bonds; metal ion binding; protein binding

Biological Process: acetate metabolic process; metabolic process; positive regulation of oligodendrocyte differentiation

All of MyBioSource's Products are for scientific laboratory research purposes and are not for diagnostic, therapeutics, prophylactic or in vivo use. Through your purchase, you expressly represent and warrant to MyBioSource that you will properly test and use any Products purchased from MyBioSource in accordance with industry standards. MyBioSource and its authorized distributors reserve the right to refuse to process any order where we reasonably believe that the intended use will fall outside of our acceptable guidelines.

While every efforts were made to ensure the accuracy of the information provided in this datasheet, MyBioSource will not be liable for any omissions or errors contained herein. MyBioSource reserves the right to make changes to this datasheet at any time without prior notice.

It is the responsibility of the customer to report product performance issues to MyBioSource within 30 days of receipt of the product. Please visit our Terms & Conditions page for more information.